As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
7 Analysts have issued a Aptevo Therapeutics Inc forecast:
7 Analysts have issued a Aptevo Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -26 -26 |
9%
9%
|
|
| EBIT (Operating Income) EBIT | -27 -27 |
9%
9%
|
|
| Net Profit | -28 -28 |
18%
18%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
| Head office | United States |
| CEO | Marvin White |
| Employees | 37 |
| Founded | 2016 |
| Website | aptevotherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


